Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.395 AUD 3.95% Market Closed
Market Cap: 717.9m AUD
Have any thoughts about
Botanix Pharmaceuticals Ltd?
Write Note

Botanix Pharmaceuticals Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Botanix Pharmaceuticals Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Botanix Pharmaceuticals Ltd
ASX:BOT
Total Current Liabilities
AU$3.7m
CAGR 3-Years
53%
CAGR 5-Years
-4%
CAGR 10-Years
28%
Recce Pharmaceuticals Ltd
ASX:RCE
Total Current Liabilities
AU$15.1m
CAGR 3-Years
141%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Total Current Liabilities
AU$313.9m
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Total Current Liabilities
AU$9m
CAGR 3-Years
56%
CAGR 5-Years
47%
CAGR 10-Years
14%
Probiotec Ltd
ASX:PBP
Total Current Liabilities
AU$46m
CAGR 3-Years
37%
CAGR 5-Years
14%
CAGR 10-Years
5%
Arovella Therapeutics Ltd
ASX:ALA
Total Current Liabilities
AU$2m
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Botanix Pharmaceuticals Ltd
Glance View

Market Cap
715m AUD
Industry
Pharmaceuticals

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT Intrinsic Value
1.114 AUD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Botanix Pharmaceuticals Ltd's Total Current Liabilities?
Total Current Liabilities
3.7m AUD

Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Total Current Liabilities amounts to 3.7m AUD.

What is Botanix Pharmaceuticals Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
28%

Over the last year, the Total Current Liabilities growth was 98%. The average annual Total Current Liabilities growth rates for Botanix Pharmaceuticals Ltd have been 53% over the past three years , -4% over the past five years , and 28% over the past ten years .

Back to Top